(PDF) P1.01-11 Named Patient Use Program for Afatinib in

P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.567

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P018 Afatinib Named Patient Use Program in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

Journal of Thoracic Oncology

Respiratory Medicine

English

Afatinib in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives

English

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC With Progression on Prior EGFR-TKI

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology

Respiratory Medicine

English

Refractory Severe Esophagitis During Durvalumab Therapy in a Patient With Locally Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-95 Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients With ROS1 Rearrangement——A Single Chinese Cancer Institute Experience

Journal of Thoracic Oncology

Respiratory Medicine

English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

English

P1.01-110 Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated With Afatinib

Journal of Thoracic Oncology

Respiratory Medicine

English